Research Site

Toledo 45007

3 studies enrolling now · 11 studies all time

What they study most

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Breast Cancer, Early Breast Cancer, Chronic Lymphocytic Leukemia, ER-Positive HER2-Negative Breast Cancer, Heart Failure, Peripheral Artery Disease, Primary Membranous Nephropathy, Pulmonary Hypertension (World Health Organization Group 2)

Studies at this site

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer — Recruiting now
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Recruiting now
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) — Running, not enrolling
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck — Completed
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 — Completed
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer — Stopped early
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease — Completed
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) — Stopped early